Lenasience commenced a Phase II clinical trial for localized advanced non-small cell lung cancer on July 16, 2026, assessing the efficacy and safety in 27 cases. The trial is scheduled from April 2026 to March 2029.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4889","jir_company_name":"Lenasience","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-07-17","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4889-20260717-01.pdf","jir_short_summary":"Lenasience commenced a Phase II clinical trial for localized advanced non-small cell lung cancer on July 16, 2026, assessing the efficacy and safety in 27 cases. The trial is scheduled from April 2026 to March 2029.","jir_summary":"### Overview of the Clinical Trial\nLenasience has initiated a Phase II physician-led clinical trial for localized advanced non-small cell lung cancer. The study targets 27 patients who are unsuitable for curative surgery, evaluating the efficacy and safety of combining chemoradiotherapy and the immune checkpoint inhibitor durvalumab with the PAI-1 inhibitor RS5614. The trial is being conducted at 12 medical institutions domestically, and will run from April 2026 to March 2029. This aims to enhance the immune therapy effects while suppressing side effects.\n\n### Future Outlook and Corporate Activities\nThe initiation of this clinical trial is expected to advance the company's cancer treatment development and may have a positive impact on financial results for the fiscal year ending March 2027. Supported by AMED, the trial costs will be partly subsidized, and the company aims to establish new therapies that enhance antitumor effects and suppress lung injuries. Continued collaboration with domestic medical institutions will keep attention on trial progress and outcomes.","jir_financial_highlights":"Trial Start Date: July 16, 2026 (Unknown)\nNumber of Cases: 27 cases (Unknown)\nClinical Trial Period: April 2026 to March 2029 (Unknown)","jir_category":"","jir_hashtags":"#Lenasience, #IRRelated, #JapaneseStocks","jir_key_figures":"Trial Start Date: July 16, 2026\nNumber of Cases: 27 cases\nClinical Trial Period: April 2026 to March 2029","jir_meta_title":"\u3010Lenasience\u3011 Initiation of Lung Cancer Clinical Trial | July 2026","jir_meta_description":"Lenasience has initiated a Phase II clinical trial for localized advanced non-small cell lung cancer, evaluating safety and efficacy. Administration to patients was carried out in July 2026.","jir_og_title":"\u3010Lenasience\u3011 Lung Cancer Clinical Trial Initiation | July 2026","jir_og_description":"Lenasience has started a Phase II clinical trial for localized advanced lung cancer, drawing attention to the progress of the trial and future prospects.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57877,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-82387","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n